ACAT1 and hepatocellular carcinoma: Our results suggest that ACAT inhibition could also be applied to optimise TCR-gene-modified T cells and other adoptive cell therapies being developed for HBV and tumours including HCC, as in a recent study using click chemistry to deliver Avasimibe to CAR-T cells67.